Evidence map›Paper›PMID 37042149›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2023

[Thoracic

Y Xiong, B Zhang, L G Nie, S K Wu, H Zhao, D Li, J T DI

Open access · greenAbstract readCase ReportsEnglish Abstract
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 citations in OpenAlex.

  1. ThoracicJournal of thoracic disease · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Y XiongDepartment of Pathology, Peking University First Hospital, Beijing 100034, China.
B ZhangDepartment of Pathology, School of Basic Medical Sciences Peking University/Peking University Third Hospital, Beijing 100191, China.
L G NieDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China.
S K WuDepartment of Oncology, Peking University First Hospital, Beijing 100034, China.
H ZhaoDepartment of Thoracic Surgery, Peking University First Hospital, Beijing 100034, China.
D LiDepartment of Pathology, Peking University First Hospital, Beijing 100034, China.
J T DIDepartment of Pathology, Peking University First Hospital, Beijing 100034, China.
Peking University · CNPeking University First Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We explored clinicopathological features and treatment strategies for thoracic

Indexed as

AdenocarcinomaLung NeoplasmsThoracic NeoplasmsDNA HelicasesHumansImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalNuclear ProteinsTranscription FactorsDNA HelicasesImmune Checkpoint InhibitorsNuclear ProteinsSMARCA4 protein, humanTranscription FactorsImmune checkpoint inhibitorNeoadjuvant therapyPathological assessmentProgrammed cell death 1-ligand 1Thoracic SMARCA4-deficient undifferentiated tumorTumor mutation burden

Identifiers

PMID37042149
PMCPMC10091248
OpenAlexW4365135947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.